Document:

albo_Ex10_4

		
			Exhibit 10.4
		

		
			SEPARATION AGREEMENT
		

		
			 
		

		
			This Separation Agreement (this “Agreement”) is made and entered into as of October 4, 2018 (the “Execution Date”) by and between Albireo Pharma,  Inc. (“Company”) and Thomas A Shea (“Executive”).
		

		
			 
		

		
			WHEREAS, Executive'  s  employment with Company shall end on December 31,  2018 (the “Separation Date”);
		

		
			 
		

		
			WHEREAS,  Executive and Company desire to enter into a formal Agreement to memorialize the terms and conditions of Executive 's separation from Company;
		

		
			 
		

		
			WHEREAS,  this Agreement shall become effective on the eighth (8th) day after the day on which Executive signs below (such 8th day referred to herein as the “Effective Date”).
		

		
			 
		

		
			NOW,  THEREFORE,  in consideration of the mutual covenants and agreements contained herein, the parties hereby agree as follows:
		

		
			 
		

		
			1.            Separation of Employment.
		

		
			 
		

		
			(a)    Executive's  employment with Company shall end on the Separation Date as defined above.  Executive represents and warrants that he shall promptly transition his duties and responsibilities as a Company officer pursuant to Company'  s request and direction.  Following the Separation Date,  Executive shall not be and shall not represent himself as an employee or agent of Company.
		

		
			 
		

		
			(b)   To the extent not theretofore paid or provided,  Company shall pay or provide to Executive the following (together the “Final Compensation”): (i) Executive'  s Base Salary through the Separation Date;  (ii) any accrued but unused vacation pay;  and (iii) any other amounts or benefits required to be paid or provided or which Executive is entitled to receive under any plan,  program,  policy or practice or contract or agreement of Company and its affiliated companies.
		

		
			 
		

		
			2.     Separation Benefit. Provided that Executive (A) remains employed in good standing through the Separation Date,  (B) executes and does not revoke this Agreement,  and (C) executes and does not revoke the Supplemental Release attached as Exhibit A  (the “Supplemental Release”), Company agrees to provide Executive with the following payments and benefits (together, the “Separation Benefit”):
		

		
			 
		

		
			(a)    Company shall pay to Executive twelve (12) months of severance pay based on Executive's Base Salary as of the Separation Date. In accordance with Section 5(d)(iii) of Executive'  s employment agreement with Company dated August 4, 2016 (the “Employment Agreement”),  the foregoing severance pay shall be paid in equal installments over the 12-month severance period in accordance with Company'  s normal payroll practices and commencing on the first regular payday for executives following the Supplemental Effective Date (as defined in the Supplemental Release).
		

		
			 
		

		
			(b)      Provided that Executive properly and timely elects to continue Executive's health and dental insurance coverage to the extent allowed under COBRA (or mini-COB RA),  Company will contribute towards the cost of such COBRA (or mini-COBRA) coverage in the same amount as if Executive were actively employed, plus any COBRA (or mini-COBRA) administration fees, until the earlier of: (i) December 31, 2019; or (ii) the date Executive becomes eligible for coverage under the group health plan of another employer (the “COBRA Contribution Period”). During this COBRA Contribution Period, Executive will be required to contribute towards the cost of the COBRA (or mini-COBRA) premium in the same amount as if Executive was actively employed, which Executive agrees to timely
		

		
			 
		

		
			
		

		
			

		 

		

			1

		

 

		

		
			 
		

		
			pay. After the COBRA Contribution Period, Executive will be responsible for the full cost of any such COBRA (or mini-COBRA) premiums. Executive agrees to promptly notify Company if Executive becomes eligible under the group health plan of another employer prior to December 31, 2019. Following the expiration or termination of the COBRA Contribution Period, Executive may at Executive's sole cost and expense continue COBRA coverage for Executive and Executive 's spouse and eligible dependents, for the duration permitted by and subject to all the requirements of COBRA.
		

		
			 
		

		
			(c)     Notwithstanding anything in the Option Agreements or Incentive Plans to the contrary, the options that are vested and exercisable as of the Separation Date (as summarized in Section 3(a)), to the extent not previously exercised, shall remain exercisable until the one (1) year anniversary of the Separation Date.
		

		
			 
		

		
			Executive acknowledges and agrees that the Separation Benefit is not intended to and does not constitute a severance plan or confer a benefit on anyone other than the parties. Executive further acknowledges that except for the Separation Benefit and the Final Compensation, Executive is not now and shall not in the future be entitled to any other compensation from Company including, without limitation, other wages, commissions, bonuses, vacation pay, holiday pay, paid time off, stock, stock options, equity, or any other form of compensation or benefit.
		

		
			 
		

		
			3.            Equity.
		

		
			 
		

		
			(a)      Executive was granted options to purchase 125,947 shares of Company's common stock pursuant to the terms of the Stock Option Agreements dated November 3, 2016, January 20, 2017, August 21, 2017 and June 8, 2018 (collectively, the “Option Agreements”) and the terms of Company ' s 2016 Equity Incentive Plan, 2017 Equity Incentive Plan and 2018 Equity Incentive Plan, respectively (collectively, the “Incentive Plans “). Assuming Executive remains employed in good standing through the Separation Date, as of the Separation Date, 54,217 shares shall be vested (the “Vested Shares”) and the remaining 71,730 shares shall be unvested (the “Unvested Shares”) pursuant to the Option Agreements. Executive acknowledges and agrees that, upon the Separation Date, the options with respect to the Unvested Shares shall be terminated and he shall have no right(s) to exercise the options with respect to any portion of such Unvested Shares.
		

		
			 
		

		
			(b)
		

		
			 
		

		
			(c)      Except for Executive's ability to exercise the Vested Shares in accordance with the Incentive Plans and the Option Agreements , Executive represents and agrees that (i) he does not own any common stock, stock options, or other equity interest in Company, (ii) he has no right to acquire any further stock options, common stock, equity or other interest in Company under the Option Agreements and/or the Incentive Plans and he shall not in the future have any right to acquire any equity or other interest in Company under the Incentive Plans or the Option Agreements , and (iii) he shall not have any right to vest in any stock or stock options under any Company equity, stock and/or stock option plan or program (of whatever name or kind) that he may have participated in or were eligible to participate in during his employment with Company.
		

		
			 
		

		
			4.     Ongoing Covenants; Return of Property. Executive expressly acknowledges and agrees that Executive shall adhere to the provisions of Section 7 (“Confidential Information”), Section 8 (“Assignment of Rights to Intellectual Property”) and Section 9 (“Restricted Activities”) of the Employment Agreement, which are expressly incorporated by reference herein and shall survive the signing of this Agreement. Executive further acknowledges and agrees that Executive shall abide by any and all Company policies and applicable common law and statutory obligations relating to the protection of Company' s trade secrets and confidential and proprietary information.
		

		
			 
		

		
			5.     Confidentiality.  Information relating to the negotiation of this Agreement and the terms of this Agreement, shall be held confidential by Executive and shall not be publicized or disclosed to: 
		

		
			 
		

		
			
		

		
			

		 

		

			2

		

 

		

		
			 
		

		
			(a) any person, other than an immediate family member, legal counsel or financial advisor who agrees to be bound by these confidentiality obligations); (ii) any business entity; or (iii) any government agency, except as mandated and permitted by state or federal law. This section shall not prohibit or limit either party from participating in an investigation with a state or federal agency if requested by the agency to do so or prohibit either party from disclosing the terms of this Agreement as necessary and appropriate pursuant to legal requirements and standard recordkeeping and accounting practices.
		

		
			 
		

		
			6.     Non-Disparagement. Neither party shall make any statements that are professionally or personally disparaging to the other party (including Company ' s officers, directors , employees and consultants) , including any statements that disparage any person, product, service, finances, financial condition, or capability.
		

		
			 
		

		
			7.     Cooperation. Following the Separation Date, Executive shall provide Executive's reasonable cooperation in connection with any action or proceeding (or any appeal from any action or proceeding) which relates to events occurring during Executive' s employment hereunder. Company shall reimburse Executive for any reasonable out-of-pocket expenses incurred in connection with Executive' s performance of obligations under this section at the request of Company. If Executive is entitled to be paid or reimbursed for any expenses under this section, then the amount reimbursable in any one calendar year shall not affect the amount reimbursable in any other calendar year, and the reimbursement of an eligible expense must be made no later than December 31 of the year after the year in which the expense was incurred.
		

		
			 
		

		
			8.            Release of Claims.
		

		
			 
		

		
			(a)    Release. Executive hereby agrees and acknowledges that by signing this Agreement and accepting the Separation Benefit, and for other good and valuable consideration provided for in this Agreement, Executive is waiving and releasing Executive' s right to assert any form of legal claim against Company11 whatsoever for any alleged action, inaction or circumstance existing or arising from the beginning of time through the Execution Date. Executive ' s waiver and release herein is intended to bar any form of legal claim, charge, complaint or any other form of action (jointly referred to as “Claims”) against Company seeking any form of relief including, without limitation, equitable relief (whether declaratory, injunctive or otherwise), the recovery of any damages or any other form of monetary recovery whatsoever (including, without limitation , back pay, front pay, compensatory damages , emotional distress damages, punitive damages, attorneys ' fees and any other costs) against Company, for any alleged action, inaction or circumstance existing or arising through the Execution Date. Without limiting the generality of the foregoing, Executive specifically waives and releases Company from any waivable claim arising from or related to Executive's employment relationship with Company through the Execution Date including, without limitation : (i) Claims under any Massachusetts or other state or federal statute, regulation or executive order (as amended) relating to employment, discrimination , fair employment practices, wages, hours or other terms and conditions of employment, including but not limited to the Age Discrimination in Employment Act and Older Workers Benefit Protection Act, the Civil Rights Acts of 1866 and 1871 and Title VII of the Civil Rights Act of 1964 and the Civil Rights Act of 1991, the Equal Pay Act, the Americans With Disabilities Act, the Genetic Information Non-Discrimination Act, the Uniformed Services Employment and Reemployment Rights Act of 1994, the Lilly Ledbetter Fair Pay Act, the National Labor Relations Act, the Family and Medical Leave Act, the Employee Retirement Income Security Act of 1974, COBRA, the Worker Adjustment and Retraining Notification Act, the Massachusetts Fair Employment Practices Statute, the Massachusetts Equal Rights Act, the Massachusetts Civil Rights Act, the Massachusetts Privacy Statute, the Massachusetts Sexual Harassment Statute, the Massachusetts Wage Act, the Massachusetts Minimum Fair Wages Act, the Massachusetts Equal Pay Act, and any similar Massachusetts or other state or federal
		

		
			 
		

		

		
			11    For purposes of this section,  “Company” means Albireo Pharma,  Inc. and its divisions,  affiliates,  parents, subsidiaries and related entities,  and its and their owners,  shareholders,  partners,  directors,  officers,  employees,  trustees,  agents,  successors and assigns.
		

		
			
		

		
			

		 

		

			3

		

 

		

		
			 
		

		
			statute, regulation or executive order (as amended) relating to or other terms and conditions of employment. Please note that this section specifically includes a waiver and release of Claims regarding payments or amounts covered by the Massachusetts Wage Act or the Massachusetts Minimum Fair Wages Act, including hourly wages, salary, overtime, minimum wages, commissions, vacation pay, holiday pay, sick leave pay, dismissal pay, bonus pay or severance pay; (ii) Claims under any Massachusetts or other state or federal common law theory including, without limitation, wrongful discharge, breach of express or implied contract, promissory estoppel, unjust enrichment, breach of a covenant of good faith and fair dealing, violation of public policy, defamation, interference with contractual relations, intentional or negligent infliction of emotional distress, invasion of privacy, misrepresentation , deceit, fraud or negligence or any claim to attorneys' fees under any applicable statute or common law theory of recovery; and (iii) any other Claim arising under other state or federal law. Notwithstanding anything in this section to the contrary, this section does not release Company from any obligation expressly set forth in this Agreement and shall not act as a waiver or release of any claims that Executive cannot by law waive or release.
		

		
			 
		

		
			(b)          No Claims Filed; Release Limitation. As a condition of Company entering into this Agreement, Executive further represents that he has not filed against Company any complaints, claims or lawsuits with any court, administrative agency or arbitral tribunal prior to the Execution Date, and that he has not transferred to any other person any such complaints, claims or lawsuits. Executive understands that nothing contained in this Agreement limits his ability to file a charge or complaint with the Equal Employment Opportunity Commission, the National Labor Relations Board, the Occupational Safety and Health Administration, the Securities and Exchange Commission or any other federal, state or local governmental agency or commission (the “Government Agencies”). Executive further understands that this Agreement does not limit his ability to communicate with any Government Agencies or otherwise participate in any investigation or proceeding that may be conducted by any Government Agencies, including providing documents or other information, without notice to Company. This Agreement does not limit Executive' s right to receive an award for information provided to any Government Agencies. Executive understands, however, that, except as limited by the immediately preceding sentence, by signing this Agreement, Executive waives his right to any monetary recovery in connection with Government Agencies proceedings and Executive waives his right to file a claim seeking monetary damages in any court, administrative agency or arbitral tribunal.
		

		
			 
		

		
			(c)           Acknowledgement.  Executive acknowledges and agrees that, but for providing this waiver and release, Executive would not be receiving the Separation Benefit provided to Executive under the terms of this Agreement.
		

		
			 
		

		
			9.            ADEA/OWBP A Review and Revocation Period. Executive and Company acknowledge that Executive has specific rights under the Age Discrimination in Employment Act (“ADEA'') and the Older Workers Benefit Protection Act (the “OWBPA”), which prohibit discrimination on the basis of age. It is Company ' s desire and intent to make certain that Executive fully understands the provisions and effects of this Agreement, which includes a release of claims under the ADEA and OWBPA. To that end, Executive has been encouraged and given the opportunity to consult with legal counsel for the purpose of reviewing the terms of this Agreement. Consistent with the provisions of the ADEA and OWBPA, Company also is providing Executive with twenty one (21) days from the Execution Date in which to consider and accept the terms of this Agreement by signing below and returning it to Jason Duncan, General Counsel, Albireo Pharma, Inc., 10 Post Office Square , Suite 502 South, Boston, MA 02109. Executive may rescind Executive's assent to this Agreement if, within seven (7) days after Executive signs this Agreement, Executive delivers by hand or send by mail (certified, return receipt and postmarked within such seven-day period) a notice of rescission to Jason Duncan, General Counsel, at the above- referenced address.
		

		
			 
		

		
			10.          Material Breach. A breach of any of Sections 4, 5, 6, 7 or 8 of this Agreement shall
		

		
			
		

		
			

		 

		

			4

		

 

		

		
			 
		

		
			constitute a material breach of this Agreement and, in addition to any other legal or equitable remedy available to Company, shall entitle Company to recover the Separation Benefit paid to Executive hereunder.
		

		
			 
		

		
			11.          Successors and Assigns. This Agreement is personal to Executive and shall  not  be  assignable by Executive. This Agreement shall inure to the benefit of and  be  enforceable  by  Executive' s legal representatives . Company may assign this Agreement without the consent of  Executive.  This Agreement shall inure to the benefit of and be binding upon Company and its successors and assigns.
		

		
			 
		

		
			12.          Code Section 409A. Both Executive and Company intend this Agreement to be in compliance with Section 409A of the Internal Revenue Code of 1986 (as amended). Executive acknowledges and agrees, however, that Company does not guarantee the tax treatment or tax consequences associated with any payment or benefit arising under this Agreement, including, without limitation , to consequences related to Code Section 409A. In the event any payments or benefits are deemed by the IRS to be non-compliant, this Agreement, at Executive' s option, shall be modified to the extent practicable, so as to make it compliant by altering the payments or benefits, or the timing of their receipt, provided that no such modification shall increase Company' s obligations hereunder.
		

		
			 
		

		
			13.          Miscellaneous.
		

		
			 
		

		
			(a)          Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the Commonwealth of Massachusetts, without reference to principles of conflict of laws.
		

		
			 
		

		
			(b)          Captions. The captions of this Agreement are not part of the provisions hereof and shall have no force or effect.
		

		
			 
		

		
			(c)           Amendments. This Agreement may not be amended or modified otherwise than by a written agreement executed by the parties hereto or their respective successors and legal representatives.
		

		
			 
		

		
			(d)          Notices. All notices and other communications hereunder shall be in writing and shall be given by hand delivery to the other party  or by  registered or certified mail,  return receipt requested,  postage prepaid,  addressed as follows:
		

		
			 
		

			
					
						 

					
					
						 

				
	
					
						If to Executive:

					
					
						Thomas A. Shea

				
	
					
						 

					
					
						8 Villa Drive

				
	
					
						 

					
					
						Medway,  MA 02053

				
	
					
						 

					
					
						 

				
	
					
						If to Company:

					
					
						Albireo Pharma,  Inc.

				
	
					
						 

					
					
						10 Post Office Square

				
	
					
						 

					
					
						Suite 502 South

				
	
					
						 

					
					
						Boston,  MA 02109

				
	
					
						 

					
					
						Attention: General Counsel

				

		
			 
		

		
			
		

		
			

		 

		

			5

		

 

		

		
			 
		

		
			or to such other address as either party shall have furnished to the other in writing in accordance herewith. Notice and communications shall be effective when actually received by the addressee.
		

		
			 
		

		
			(e)           Severability. The invalidity or unenforceability of any provision of this Agreement shall not affect the validity or enforceability of any other provision of this Agreement.
		

		
			 
		

		
			(f)           Withholding. Company may withhold from any amounts payable under this Agreement such Federal, state, local or foreign taxes as shall be required to be withheld pursuant to any applicable law or regulation.
		

		
			 
		

		
			(g)          Waivers.  Executive's or Company's failure to insist upon strict compliance with any prov1s1on of this Agreement or the failure to assert any right Executive or Company may have hereunder, shall not be deemed to be a waiver of such provision or right or any other provision or right of this Agreement.
		

		
			 
		

		
			(h)          Entire Agreement. This Agreement and the agreements and/or the agreement sections explicitly referenced as surviving herein (including the Incentive Plans,  the Option Agreements , and Sections 7,  8 and 9 of the Employment Agreement) ,  contain the entire agreement between Company and Executive with respect to the subject matter hereof and, from and after the Effective Date,  shall supersede any other agreement between the parties with respect to the subject matterhereof.
		

		
			 
		

		
			(i)           Counterparts; Scanned Signatures. This Agreement may be executed in one or more counterparts,  all of which shall be considered one and the same agreement ,  and shall become a binding agreement when one or more counterparts have been signed by each party and delivered to the other party. A counterpart executed and delivered by PDF or facsimile shall be sufficient for the Agreement to become effective.
		

		
			 
		

		
			IN WITNESS WHEREOF,  Executive has hereunto set Executive 's hand and, pursuant to the authorization from the Board,  Company has caused these presents to be executed in its name on its behalf,  all as of the day and year first above written.
		

		
			 
		

			
					
						THOMAS A. SHEA

					
					
						 

					
					
						ALBIREO PHARMA,  INC.

				
	
					
						 

					
					
						 

					
					
						 

				
	
					
						 

					
					
						 

					
					
						 

				
	
					
						Signed Name

					
					
						 

					
					
						 

				
	
					
						 

					
					
						 

					
					
						By:

				
	
					
						 

					
					
						 

					
					
						Name:

				
	
					
						 

					
					
						 

					
					
						 

				
	
					
						 

					
					
						 

					
					
						 

				
	
					
						Printed Name

					
					
						 

					
					
						Title: President and CEO

				

		
			 
		

		
			 
		

		
			 
		

		
			

		 

		

			6

		

 

		

		
			 
		

		
			EXHIBIT A
		

		
			 
		

		
			SUPPLEMENTAL RELEASE
		

		
			 
		

		
			This Supplemental Release (this “Release”) is made and entered into as of December 31,  2018 (the “Separation Date”) by and between Albireo Pharma,  Inc. (“Company”) and Thomas A. Shea (“Executive”).
		

		
			 
		

		
			1.            Release of Claims. Executive hereby agrees and acknowledges that by signing this Release and accepting the Separation Benefit (as defined in the Separation Agreement between Company  and Executive,  dated October 4,  2018 (the “Separation Agreement “)),  and for other good and valuable consideration provided for in the Separation Agreement ,  Executive is waiving and releasing Executive's right to assert any form of legal claim against Company2/ whatsoever for any alleged action,  inaction or circumstance existing or arising from the beginning of time through the Separation Date.  Executive's waiver and release herein is intended to bar any form of legal claim,  charge ,  complaint or any other form of action (jointly referred to as “Claims”) against Company seeking any form of relief including ,  without limitation , equitable relief (whether declaratory,  injunctive or otherwise),  the recovery of any damages or any other form of monetary recovery whatsoever (including ,  without limitation,  back pay,  front pay, compensator y damages,  emotional distress damages, punitive damages,  attorneys '  fees and any other costs) against Company,  for any alleged action,  inaction or circumstance existing or arising through the Separation Date. Without limiting the generality of the foregoing,  Executive specifically waives and releases Company from any waivable claim arising from or related to Executive '  s employment relationship with Company through the Separation Date including, without limitation: (i) Claims under any Massachusetts or other state or federal statute,  regulation or executive order (as amended) relating to employment,  discrimination,  fair employment practices,  wages, hours or other terms and conditions of employment,  including but not limited to the Age Discrimination in Employment Act and Older Workers Benefit Protection Act,  the Civil Rights Acts of 1866 and 1871 and Title VII of the Civil Rights Act of 1964 and the Civil Rights Act of 1991,  the Equal Pay Act,  the Americans With Disabilities Act,  the Genetic Information Non-Discrimination Act,  the Uniformed Services Employment and Reemployment Rights Act of 1994,  the Lilly Ledbetter Fair Pay  Act,  the National Labor Relations Act,  the Family and Medical Leave Act,  the Employee Retirement Income Security Act of 1974,  COBRA,  the Worker Adjustment and Retraining Notification Act,  the Massachusetts Fair Employment Practices Statute, the Massachusetts Equal Rights Act, the Massachusetts Civil Rights Act, the  Massachusetts Privacy Statute,  the Massachusetts Sexual Harassment Statute,  the Massachusetts Wage Act,  the Massachusetts Minimum Fair Wages Act,  the Massachusetts Equal Pay Act, and any similar Massachusetts or other state or federal statute,  regulation or executive order (as amended) relating to or other terms and conditions of employment. Please note that this section specifically includes a waiver and release of Claims regarding payments or amounts covered by the Massachusetts Wage Act or the Massachusetts Minimum Fair Wages Act,  including hourly wages,  salary,  overtime, minimum wages, commissions , vacation pay, holiday pay,  sick leave pay, dismissal pay,  bonus pay or severance pay; (ii) Claims under any Massachusetts or other state or federal common law theory in cluding,  without limitation ,  wrongful discharge,  breach of express or implied contract, promissory estoppel,  unjust enrichment, breach of a covenant of good faith and fair dealing,  violation of public policy,  defamation ,  interference with contractual relations,  intentional or negligent infliction of emotional distress, invasion of privacy,  misrepresentation , deceit,  fraud or negligence or any claim to attorneys '  fees under any applicable statute or common law theory of recovery;  and (iii) any other Claim arising under other state or federal law. Notwithstanding anything in this section to the contrary, this section does not release Company from any
		

		
			 
		

		

		
			21    For purposes of this section,  “Company” means Albireo Pharma,  Inc. and its divisions,  affiliates, parents,  subsidiaries and related entities,  and its and their owners,  shareholders,  partners,  directors,  officers,  employees,  trustees,  agents,  successors and assigns.
		

		
			 
		

		
			
		

		
			

		 

		

			A-1

		

 

		

		
			 
		

		
			obligation expressly  set forth in the Separation Agreement and shall not act as a waiver or release of any claims that Executive cannot by law waive or release.
		

		
			 
		

		
			2.            No Claims Filed; Release Limitation. As a condition of Company entering into this Release,  Executive further represents that he has not filed against Company any complaints,  claims or lawsuits with any court,  administrative agency or arbitral tribunal prior to the Separation Date,  and that he has not transferred to any other person any such complaints, claims or lawsuits. Executive understands that nothing contained in this Release limits his ability to file a charge or complaint with the Equal Employment Opportunity Commission, the National Labor Relations Board,  the Occupational Safety and Health Administration,  the Securities and Exchange Commission or any other federal,  state or local governmental agency or commission (the “Government Agencies”). Executive further understands that this Release does not limit his ability to communicate with any Government Agencies or otherwise participate in any investigation or proceeding that may be conducted by any Government Agencies, including providing documents or other information,  without notice to Company.  This Release does not limit Executive's right to receive an award for information provided to any Government Agencies. Executive understands,  however,  that,  except as limited by the immediately preceding sentence,  by signing this Release,  Executive waives his right to any monetary recovery in connection with Government Agencies proceedings and Executive waives his right to file a claim seeking monetary damages in any court,  administrative agency or arbitral tribunal.
		

		
			 
		

		
			3.            ADEA/OWBPA Review and Revocation Period.  Executive and Company  acknowledge that Executive has specific rights under the Age Discrimination in Employment Act (“ADEA”) and the Older Workers Benefit Protection Act (the “OWBPA”),  which prohibit discrimination on the basis of age. It is Company'  s desire and intent to make certain that Executive fully understands the provisions and effects of this Release,  which includes a release of claims under the ADEA and OWBPA. To that end, Executive has been encouraged and given the opportunity to consult with legal counsel for the purpose of reviewing the terms of this Release. Consistent with the provisions of the ADEA and OWBPA, Company also is providing Executive with twenty one (21) days from the Separation Date in which to consider and accept the terms of this Release by signing below and returning it to Jason Duncan,  General Counsel, Albireo Pharma,  Inc., 10 Post Office Square, Suite 502 South, Boston, MA 02109. Executive may rescind Executive's assent to this Release  if,  within seven (7) days after Executive signs this Release,  Executive  delivers by hand or send by mail (certified,  return receipt and postmarked within such seven-  day period) a notice of rescission to Jason Duncan,  General Counsel, at the above-referenced address. The eighth (8th ) day following Executive '  s signing  of this  Release  is the effective  date  of this  Release  (such  date,  the “Supplemental Effective Date”).
		

		
			 
		

		
			4.            Acknowledgement. Executive acknowledges and agrees that,  but for providing this waiver and release,  Executive would not be receiving the Separation Benefit provided to Executive under the terms of the Separation Agreement.
		

		
			 
		

			
					
						Confirmed And Agreed :

					
					
						 

				
	
					
						 

					
					
						 

				
	
					
						 

					
					
						 

				
	
					
						 

					
					
						 

				
	
					
						Thomas A. Shea

					
					
						 

				
	
					
						 

					
					
						 

				
	
					
						Dated:

					
					
						 

					
					
						 

				

		
			 
		

		 

		

			A-2albo_Ex10_5

		
			Exhibit 10.5
		

		
			 
		

		
			Option No.  86
		

		
			 
		

		
			ALBIREO PHARMA, INC.
		

		
			 
		

		
			Non-Qualified Stock Option Grant Notice
		

		
			 
		

			
					
						I.           Name and Address of Participant:

					
					
						Simon N.R. Harford

					
						50 Malden Street, Apt. 301

					
						Boston,  MA 02118

				
	
					
						 

					
					
						 

				
	
					
						2.           Date of Option Grant:

					
					
						October 10, 2018

				
	
					
						 

					
					
						 

				
	
					
						3.           Maximum Number of Shares for which this Option is exercisable:

					
					
						37,500 shares of Common Stock

				
	
					
						 

					
					
						 

				
	
					
						4.           Exercise (purchase) price per share:

					
					
						$27.98

				
	
					
						 

					
					
						 

				
	
					
						5.           Option Expiration Date:

					
					
						October 9, 2028

				
	
					
						 

					
					
						 

				
	
					
						6.           Vesting Start Date:

					
					
						October 10, 2018

				

		
			 
		

		
			7.           Vesting Schedule: This Option shall become exercisable (and the Shares issued upon exercise shall be vested) as follows provided the Participant is an Employee of the Company or of an Affiliate on the applicable vesting date:
		

		
			 
		

		
			This Option vests and becomes exercisable as to 25% of the underlying Shares on October 10,  2019 and as to the remainder of the underlying Shares in equal installments on the 10th day of 12 consecutive calendar quarters beginning on January 10,  2020 and ending on October 10, 2022.
		

		
			 
		

		
			The foregoing rights are cumulative and are subject to the other terms and conditions of this Agreement.
		

		
			 
		

		
			The Company and the Participant acknowledge receipt of this Non-Qualified Stock Option Grant Notice and agree to the terms of the Non-Qualified Stock Option Agreement attached hereto,  and the terms of this Option Grant as set forth above.
		

		
			 
		

		
			 
		

			
					
						 

					
					
						 

					
					
						 

				
	
					
						 

					
					
						 

					
					
						ALBIREO PHARMA, INC.

				
	
					
						 

					
					
						 

					
					
						 

				
	
					
						 

					
					
						By:

					
					
						 

				
	
					
						 

					
					
						 

					
					
						Name: Ronald H.W. Cooper

				
	
					
						 

					
					
						 

					
					
						Title: President and Chief Executive Officer

				
	
					
						 

					
					
						 

					
					
						 

				
	
					
						 

					
					
						 

					
					
						 

				
	
					
						 

					
					
						 

					
					
						 

				
	
					
						 

					
					
						 

					
					
						 

				
	
					
						 

					
					
						 

					
					
						Participant:

				

		
			 
		

		
			 
		

		
			

		 

 

		

		
			 
		

		
			ALBIREO PHARMA, INC.
		

		
			 
		

		
			NON-QUALIFIED STOCK OPTION AGREEMENT
		

		
			 
		

		
			AGREEMENT made as of the date of grant set forth in the Non-Qualified Stock Option Grant Notice (the "Stock Option Grant Notice")  by  and  between  Albireo  Pharma,  Inc.  (the “Company") ,  a Delaware corporation,  and the individual whose name appears on the Stock Option Grant Notice (the "Participant").
		

		
			 
		

		
			WHEREAS,  the Company desires to grant to the Participant an Option to purchase shares (the "Shares") of its common stock, $0.01 par value per share ("Common Stock"), as an inducement material to the Participant's entering into employment as Chief Financial Officer of the Company starting October 10, 2018 (the "Start Date"), in accordance with the terms of an employment agreement with the Company dated October 4, 2018; and
		

		
			 
		

		
			WHEREAS, the Company and the Participant each intend that the Option granted herein shall be a non-qualified stock option.
		

		
			 
		

		
			NOW, THEREFORE, in consideration of the mutual covenants hereinafter set forth and for other good and valuable consideration, the parties hereto agree as follows:
		

		
			 
		

		
			1.            DEFINITIONS.
		

		
			 
		

		
			Unless otherwise specified or unless the context otherwise requires,  the following terms,  as used in this Agreement, have the following meanings:
		

		
			 
		

		
			Administrator means the Board of Directors, unless it has delegated power to act on its behalf to the Committee,  in which case the term Administrator means  the Committee.
		

		
			 
		

		
			Affiliate means a corporation which, for purposes of Section 424 of the Code, is a parent or subsidiary of the Company,  direct or indirect.
		

		
			 
		

		
			Board of Directors means the Board of Directors of the Company.
		

		
			 
		

		
			Cause means,  with respect to the Participant:  (a) dishonesty with respect to the Company or any Affiliate,  (b) insubordination ,  substantial malfeasance or non-feasance of duty, (c) unauthorized disclosure of confidential information,
		

		
			(d) breach by the Participant of any provision of any employment, consulting, advisory, nondisclosure, non-competition or similar agreement between the Participant and the Company or any Affiliate, and (e) conduct substantially prejudicial to the business of the Company or any Affiliate;  provided,  however, that any provision in an agreement between the Participant and the Company or an Affiliate, which contains a conflicting definition of Cause for termination and which is in effect at the time of such termination,  shall supersede this definition. The determination of the Administrator as to the existence of Cause will be conclusive on the Participant and the Company.
		

		
			 
		

		
			
		

		
			

		 

		

			 

		

 

		

		
			 
		

		
			Code means the United States Internal Revenue Code of 1986, as amended, including any successor statute, regulation and guidance thereto.
		

		
			 
		

		
			Committee means the committee of the Board of Directors to which the Board of Directors has delegated power to act.
		

		
			 
		

		
			Corporate Transaction means the Company is consolidated with or acquired by another entity in a merger, consolidation, or sale of all or substantially all of the Company's assets or the acquisition of all of the outstanding voting stock of the Company in a single transaction or a series of related transactions by a single entity,  other than a transaction to merely change the state of incorporation.
		

		
			 
		

		
			Disability or Disabled means permanent and total disability as defined in Section 22(e)(3) of the Code.
		

		
			 
		

		
			Director means any member of the Board of Directors.
		

		
			 
		

		
			Employee means any employee of the Company or of an Affiliate (including, without limitation, an employee who is also serving as an officer or director of the Company or of an Affiliate) .
		

		
			 
		

		
			Exchange Act means the Securities Exchange Act of 1934, as amended.
		

		
			 
		

		
			Fair Market Value of a Share of Common Stock means:
		

		
			 
		

		
			If the Common Stock is listed on a national securities exchange or traded in the over-the-counter market and sales prices are regularly reported for the Common Stock,  the closing or, if not applicable, the last price of the Common Stock on the composite tape or other comparable reporting system for the trading day on the applicable date and if such applicable date is not a  trading day,  the last market trading day prior to such date;
		

		
			 
		

		
			If the Common Stock is not traded on a national securities exchange but is traded on the over-the-counter market, if sales prices are not regularly reported for the Common Stock for the trading day referred to in clause (1),  and if bid and asked prices for the Common Stock are regularly reported, the mean between the bid and the asked price for the Common Stock at the close of trading in the over-the-counter market for the trading day on which Common Stock was traded on the applicable date and if such applicable date is not a trading day, the last market trading day prior to such date; and
		

		
			 
		

		
			If the Common Stock is neither listed on a national securities exchange nor traded in the over-the-counter market, such value as the Administrator, in good faith, shall determine in compliance with applicable laws.
		

		
			 
		

		
			Non-Qualified Option means an option which is not intended to qualify as an incentive stock option under Section 422 of the Code.
		

		
			 
		

		
			
		

		
			

		 

		

			2

		

 

		

		
			 
		

		
			Option means a Non-Qualified Option granted as an inducement award under Nasdaq Listing Rule 5635(c)(4).
		

		
			 
		

		
			Securities Act means the Securities Act of 1933,  as amended.
		

		
			 
		

		
			Survivor means the deceased Participant's legal representatives and/or any person or persons who acquire the Option by will or by the laws of descent and distribution.
		

		
			 
		

		
			2.            GRANT OF OPTION.
		

		
			 
		

		
			The Company hereby grants to the Participant the right and option to purchase all or any part of an aggregate of the number of Shares set forth in the Stock Option Grant Notice,  on the terms and conditions and subject to all the limitations set forth herein and under United States securities and tax laws.
		

		
			 
		

		
			3.            EXERCISE PRICE.
		

		
			 
		

		
			The exercise price of the Shares covered by the Option shall be the amount per Share set forth in the Stock Option Grant Notice,  subject to adjustment, as provided in Section 10,  in the event of a stock split,  reverse stock split or other events affecting the holders of Shares after the date hereof (the "Exercise Price"). Payment shall be made in accordance with Section 6 of this Agreement.
		

		
			 
		

		
			4.            EXERCISABILITY OF OPTION.
		

		
			 
		

		
			Subject to the terms and conditions set forth in this Agreement, the Option granted hereby shall become vested and exercisable as set forth in the Stock Option Grant Notice and is subject to the other terms and conditions of this Agreement.
		

		
			 
		

		
			5.            TERM OF OPTION.
		

		
			 
		

		
			This Option shall terminate on the Option Expiration Date as specified in the Stock Option Grant Notice but shall be subject to earlier termination as provided herein.
		

		
			 
		

		
			If the Participant ceases to be an Employee of the Company or of an Affiliate for any reason other than the death or Disability of the Participant, or termination of the Participant for Cause (the "Termination Date"),  the Option to the extent then vested and exercisable pursuant to Section 4 hereof as of the Termination Date, and not previously terminated in accordance with this Agreement, may be exercised within three months after the Termination Date, or on or prior to the Option Expiration Date as specified in the Stock Option Grant Notice, whichever is earlier, but may not be exercised thereafter except as set forth below .  In such event,  the unvested portion of the Option shall not be exercisable and shall expire and be cancelled on the Termination Date.
		

		
			 
		

		
			Notwithstanding the foregoing, in the event of the Participant's Disability or death within three months after the Termination Date, the Participant or the Participant's Survivors may exercise the Option within one year after the Termination Date,  but in no event after the Option Expiration Date as specified in the Stock Option Grant Notice.
		

		
			 
		

		
			
		

		
			

		 

		

			3

		

 

		

		
			 
		

		
			In the event the Participant's service is terminated by the Company or an Affiliate for Cause,  the Participant's right to exercise any unexercised portion of this Option even if vested shall cease immediately as of the time the Participant is notified his or her service is terminated for Cause, and this Option shall thereupon terminate.  Notwithstanding anything herein to the contrary,  if subsequent to the Participant's termination, but prior to the exercise of the Option, the Administrator determines that, either prior or subsequent to the Participant's termination,  the Participant engaged in conduct which would constitute Cause,  then the Participant shall immediately cease to have any right to exercise the Option and this Option shall thereupon terminate.
		

		
			 
		

		
			In the event of the Disability of the Participant, the Option shall be exercisable within one year after the Participant's termination of service due to Disability or, if earlier, on or prior to the Option Expiration Date as specified in the Stock Option Grant Notice.  In such event,  the Option shall be exercisable:
		

		
			 
		

		
			(a)           to the extent that the Option has become exercisable but has not been exercised as of the date of the Participant's termination of service due to Disability; and
		

		
			 
		

		
			(b)          in the event rights to exercise the Option accrue periodically, to the extent of a pro rata portion through the date of the Participant's termination of service due to Disability of any additional vesting rights that would have accrued on the next vesting date had the Participant not become Disabled.  The proration shall be based upon the number of days accrued in the current vesting period prior to the date of the Participant's termination of service due to Disability.
		

		
			 
		

		
			In the event of the death of the Participant while an Employee of the Company or of an Affiliate, the Option shall be exercisable by the Participant's Survivors within one year after the date of death of the Participant or,  if earlier,  on or prior to the Option Expiration Date as specified in the Stock Option Grant Notice. In such event,  the Option shall be exercisable:
		

		
			 
		

		
			(x)          to the extent that the Option has become exercisable but has not been exercised as of the date of death;  and
		

		
			 
		

		
			(y)          in the event rights to exercise the Option accrue periodically, to the extent of a pro rata portion through the date of death of any additional vesting rights that would have accrued on the next vesting date had the Participant not died.  The proration shall be based upon the number of days accrued in the current vesting period prior to the Participant's date of death.
		

		
			 
		

		
			6.            l\.1ETHOD OF EXERCISING OPTION.
		

		
			 
		

		
			Subject to the terms and conditions of this Agreement, the Option may be exercised by written notice to the Company or its designee,  in substantially the form of Exhibit A attached
		

		
			 
		

		
			
		

		
			

		 

		

			4

		

 

		

		
			 
		

		
			hereto (or in such other form acceptable to the Company, which may include electronic notice). Such notice shall state the number of Shares with respect to which the Option is being exercised and shall be signed by the person exercising the Option (which signature may be provided electronically in a form acceptable to the Company). Payment of the Exercise Price for such Shares shall be made (a) in United States dollars in cash or by check;  or (b) at the discretion of the Administrator ,  through delivery of shares of Common Stock held for at least six months (if required to avoid negative accounting treatment) having a Fair Market Value equal as of the date of the exercise to the aggregate cash exercise price for the number of Shares as to which the Option is being exercised; or (c) at the discretion of the Administrator, by having the Company retain from the Shares otherwise issuable upon exercise of the Option, a number of Shares having a Fair Market Value equal as of the date of exercise to the aggregate exercise price for the number of Shares as to which the Option is being exercised;  or (d) at the discretion of the Administrator, in accordance with a cashless exercise program established with a securities brokerage firm,  and approved by the Administrator ;  or (e) at the discretion of the Administrator ,  by any combination of (a),  (b),  (c) and (d) above;  or (f) at the discretion of the Administrator, by payment of such other lawful consideration as the Administrator may determine .  The Company shall deliver such Shares as soon as practicable after the notice shall be received,  provided, however, that the Company may delay issuance of such Shares until completion of any action or obtaining of any consent,  which the Company deems necessary under any applicable law (including,  without limitation, state securities or "blue sky" laws). The Shares as to which the Option shall have been so exercised shall be registered in the Company's share register in the name of the person so exercising the Option (or, if the Option shall be exercised by the Participant and if the Participant shall so request in the notice exercising the Option,  shall be registered in the Company's share register in the name of the Participant and another person jointly,  with right of survivorship) and shall be delivered as provided above to or upon the written order of the person exercising the Option.  In the event the Option shall be exercised, pursuant to Section 5 hereof, by any person other than the Participant, such notice shall be accompanied by appropriate proof of the right of such person to exercise the Option.  All Shares that shall be  purchased upon the exercise of the Option as provided herein shall be fully paid and nonassessable.
		

		
			 
		

		
			7.           PARTIAL EXERCISE.
		

		
			 
		

		
			Exercise of this Option to the extent above stated may be made in part at any time and from time to time within the above limits, except that no fractional share shall be issued pursuant to this Option.
		

		
			 
		

		
			8.            NON-ASSIGN ABILITY.
		

		
			 
		

		
			The Option shall not be transferable by the Participant otherwise than by will or by the laws of descent and distribution or pursuant to a qualified domestic relations order as defined by the Code or Title I of the Employee Retirement Income Security Act or the rules thereunder and the Participant,  with the approval of the Administrator ,  may transfer the Option for no consideration to or for the benefit of the Participant's Immediate Family (including, without limitation, to a trust for the benefit of the Participant's Immediate Family or to a partnership or limited liability company for one or more members of the Participant's Immediate Family), subject to such limits as the Administrator may establish ,  and the transferee shall remain subject to all the
		

		
			 
		

		
			
		

		
			

		 

		

			5

		

 

		

		
			 
		

		
			terms and conditions applicable to the Option prior to such transfer and each such transferee shall so acknowledge in writing as a condition precedent to the effectiveness of such transfer.  The term "Immediate Family" shall mean the Participant's spouse, former spouse, parents, children, stepchildren, adoptive relationships, sisters, brothers, nieces, nephews and grandchildren (and, for this purpose, shall also include the Participant). Except as provided above in this paragraph, the Option shall be exercisable, during the Participant's lifetime, only by the Participant (or, in the event of legal incapacity or incompetency, by the Participant's guardian or representative) and shall not be assigned, pledged or hypothecated in any way (whether by operation of law or otherwise) and shall not be subject to execution, attachment or similar process. Any attempted transfer, assignment, pledge, hypothecation or other disposition of the Option or of any rights granted hereunder contrary to the provisions of this Section 8, or the levy of any attachment or similar process upon the Option shall be null and void.
		

		
			 
		

		
			9.            NO RIGHTS AS STOCKHOLDER UNTIL EXERCISE.
		

		
			 
		

		
			The Participant shall have no rights as a stockholder with respect to Shares subject to this Agreement until registration of the Shares in the Company's share register in the name of the Participant. Except as is expressly provided in Section 10 of this Agreement with respect to certain changes in the capitalization of the Company, no adjustment shall be made for dividends or similar rights for which the record date is prior to the date of such registration.
		

		
			 
		

		
			10.          ADJUSTMENTS.
		

		
			 
		

		
			Upon the occurrence of any of the following events, the Participant's rights with respect to the Option shall be adjusted as hereinafter provided.
		

		
			 
		

		
			(a)           Stock Dividends and Stock Splits. If (i) the shares of Common Stock shall be subdivided or combined into a greater or smaller number of shares or if the Company shall issue any shares of Common Stock as a stock dividend on its outstanding Common Stock, or (ii) additional shares or new or different shares or other securities of the Company or other non­ cash assets are distributed with respect to such shares of Common Stock, the Option and the number of Shares deliverable thereunder shall be increased or decreased proportionately, and appropriate adjustments shall be made, including in the exercise price per share, to reflect such events.
		

		
			 
		

		
			(b)          Corporate Transactions. In the case of a Corporate Transaction, the Administrator or the board of directors of any entity assuming the obligations of the Company hereunder (the "Successor Board"), shall, as to the unexercised portion of the Option, either (i) make appropriate provision for the continuation of the Option by substituting on an equitable basis for the Shares then subject to the Option either the consideration payable with respect to the outstanding shares of Common Stock in connection with the Corporate Transaction or securities of any successor or acquiring entity; or (ii) upon written notice to the Participant, provide that the Option must be exercised (either (A) to the extent then exercisable or (B) at the discretion of the Administrator, the Option being made partially or fully exercisable for purposes of this Subclause), within a specified number of days of the date of such notice, at the end of which period the Option shall terminate); or (iii) terminate the Option in exchange for payment of an amount equal to the consideration payable upon consummation of such Corporate Transaction to the holder of the
		

		
			 
		

		
			
		

		
			

		 

		

			6

		

 

		

		
			 
		

		
			number of shares of Common Stock into which the Option would have been exercisable (either (A) to the extent then exercisable or,  (B) at the discretion of the Administrator ,  any such Options being made partially or fully exercisable for purposes of this Subclause) less the aggregate exercise price thereof For purposes of determining the payments to be made pursuant to Subclause (iii) above,  in the case of a Corporate Transaction the consideration for which,  in whole or in part,  is other than cash, the consideration other than cash shall be valued at the fair value thereof as determined in good faith by the Board of Directors .
		

		
			 
		

		
			(c)          Recapitalization or Reorganization.  In the event of a recapitalization or reorganization of the Company other than a Corporate Transaction pursuant to which securities of the Company or of another corporation are issued with respect to the outstanding shares of Common Stock, the Participant upon exercising the Option after the recapitalization or reorganization shall be entitled to receive for the price paid upon such exercise or acceptance if any,  the number of replacement securities which would have been received if the Option had been exercised prior to such recapitalization or reorganization.
		

		
			 
		

		
			(d)          Modification of Options.  Notwithstanding the foregoing, any adjustments made pursuant to Subsection (a),  (b) or (c) above shall be made only after the Administrator determines whether such adjustments would cause any adverse tax consequences,  including, but not limited to, pursuant to Section 409A of the Code. If the Administrator determines that such adjustments would constitute a modification of the Option or other adverse tax consequence to the Participant, it may in its discretion refrain from making such adjustments,  unless the Participant specifically agrees in writing that such adjustment be made and such writing indicates that the holder has full knowledge of the consequences of such “modification"  on his or her income tax treatment with respect to the Option.
		

		
			 
		

		
			(e)          Dissolution or Liquidation of the Company.  Upon the dissolution or liquidation of the Company,  the Option will terminate and become null and void;  provided,  however,  that if the rights of the Participant or the Participant's Survivors have not otherwise terminated and expired , the Participant or the Participant's Survivors will have the right immediately prior to such dissolution or liquidation to exercise the Option to the extent that the Option is exercisable as of the date immediately prior to such dissolution or liquidation.
		

		
			 
		

		
			11.          TAXES.
		

		
			 
		

		
			The Participant acknowledges and agrees that (i) any income or other taxes due from the Participant with respect to this Option or the Shares issuable pursuant to this Option shall be the Participant's responsibility;  (ii) the Participant was free to use professional advisors of his or her choice in connection with this Agreement, has received advice from his or her professional advisors in connection with this Agreement, understands its meaning and import, and is entering into this Agreement freely and without coercion or duress; (iii) the Participant has not received and is not relying upon any advice, representations or assurances made by or on behalf of the Company or any Affiliate or any employee of or counsel to the Company or any Affiliate regarding any tax or other effects or implications of the Option, the Shares or other matters contemplated by this Agreement; and (iv) neither the Administrator,  the Company,  its Affiliates, nor any of its officers or directors, shall be held liable for any applicable costs,  taxes, or penalties associated
		

		
			 
		

		
			
		

		
			

		 

		

			7

		

 

		

		
			 
		

		
			with the Option if, in fact, the Internal Revenue Service were to determine that the Option constitutes deferred compensation under Section 409A of the Code.
		

		
			 
		

		
			The Participant agrees that the Company may withhold from the Participant's remuneration, if any,  the minimum statutory amount of federal, state and local withholding taxes attributable to such amount that is considered compensation includable in such person's gross income. At the Company's discretion, the amount required to be withheld may be withheld in cash from such remuneration,  or in kind from the Shares otherwise deliverable to the Participant on exercise of the Option.  The Participant further agrees that, if the Company does not withhold an amount from the Participant's remuneration sufficient to satisfy the Company's income tax withholding obligation, the Participant will reimburse the Company on demand, in cash, for the amount under-withheld.
		

		
			 
		

		
			12.          PURCHASE FOR INVESTMENT.
		

		
			 
		

		
			Unless the offering and sale of the Shares to be issued upon the particular exercise of the Option shall have been effectively registered under the Securities Act, the Company shall be under no obligation to issue the Shares covered by such exercise unless the Company has determined that such exercise and issuance would be exempt from the registration requirements of the Securities Act and until the following conditions have been fulfilled:
		

		
			 
		

		
			(a)          The person(s) who exercise the Option shall warrant to the Company, at the time of such exercise, that such person(s) are acquiring such Shares for their own respective accounts, for investment, and not with a view to, or for sale in connection with, the distribution of any such Shares, in which event the person(s) acquiring such Shares shall be bound by the provisions of the following legend which shall be endorsed upon any certificate(s) evidencing the Shares issued pursuant to such exercise:
		

		
			 
		

		
			"The shares represented by this certificate have been taken for investment and they may not be sold or otherwise transferred by any person, including a pledgee, unless (1) either (a) a Registration Statement with respect to such shares shall be effective under the Securities Act of 1933, as amended, or (b) the Company shall have received an opinion of counsel satisfactory to it that an exemption from registration under such Act is then available, and (2) there shall have been compliance with all applicable state securities laws;" and
		

		
			 
		

		
			(b) If the Company so requires, the Company shall have received an opinion of its counsel that the Shares may be issued upon such particular exercise in compliance with the Securities Act without registration thereunder. Without limiting the generality of the foregoing, the Company may delay issuance of the Shares until completion of any action or obtaining of any consent, which the Company deems necessary under any applicable law (including without limitation state securities or "blue sky" laws).
		

		
			 
		

		
			
		

		
			

		 

		

			8

		

 

		

		
			 
		

		
			13.          RESTRICTIONS ON TRANSFER OF SHARES.
		

		
			 
		

		
			13.1        The Participant agrees that in the event the Company proposes to offer for sale to the public any of its equity securities and such Participant is requested by the Company and any underwriter engaged by the Company in connection with such offering to sign an agreement restricting the sale or other transfer of Shares, then it will promptly sign such agreement and will not transfer, whether in privately negotiated transactions or to the public in open market transactions or otherwise, any Shares or other securities of the Company held by the Participant during such period as is determined by the Company and the underwriters, not to exceed 180 days following the closing of the offering, plus such additional period of time as may be required to comply with FINRA rules or similar rules thereto promulgated by another regulatory authority (such period, the "Lock-Up Period").  Such agreement shall be in writing and in form and substance reasonably satisfactory to the Company and such underwriter and pursuant to customary and prevailing terms and conditions. Whether or not the Participant has signed such an agreement, the Company may impose stop-transfer instructions with respect to the Shares or other securities of the Company subject to the foregoing restrictions until the end of the Lock-Up Period.
		

		
			 
		

		
			13.2        The Participant acknowledges and agrees that neither the Company, its stockholders nor its directors and officers, has any duty or obligation to disclose to the Participant any material information regarding the business of the Company or affecting the value of the Shares before, at the time of, or following a termination of the service of the Participant by the Company, including, without limitation, any information concerning plans for the Company to make a public offering of its securities or to be acquired by or merged with or into another firm or entity.
		

		
			 
		

		
			14.          NO OBLIGATION TO MAINTAIN RELATIONSHIP.
		

		
			 
		

		
			The Participant acknowledges that:  (i) the Company is not by this Agreement obligated to continue the Participant as an employee of the Company or an Affiliate; (ii) the grant of the Option is a one-time benefit which does not create any contractual or other right to receive future grants of options, or benefits in lieu of options; (iii) all determinations with respect to any such future grants, including, but not limited to, the times when options shall be granted, the number of shares subject to each option, the option price, and the time or times when each option shall be exercisable, will be at the sole discretion of the Company; (iv) the value of the Option is an extraordinary item of compensation which is outside the scope of the Participant's employment or consulting contract, if any; and (v) the Option is not part of normal or expected compensation for purposes of calculating any severance, resignation, redundancy, end of service payments, bonuses, long-service awards, pension or retirement benefits or similar payments.
		

		
			 
		

		
			15.          NOTICES.
		

		
			 
		

		
			Any notices required or permitted by the terms of this Agreement shall be given by recognized courier service, facsimile, registered or certified mail, return receipt requested, addressed as follows:
		

		
			
		

		
			

		 

		

			9

		

 

		

		
			 
		

		
			Ifto the Company:
		

		
			 
		

		
			Albireo Pharma, Inc.
		

		
			10 Post Office Square, Suite 502 South
		

		
			Boston, MA 02109
		

		
			Attention: General Counsel
		

		
			 
		

		
			If to the Participant at the address set forth on the Stock Option Grant Notice
		

		
			 
		

		
			or to such other address or addresses of which notice in the same manner has previously been given. Any such notice shall be deemed to have been given upon the earlier of receipt, one business day following delivery to a recognized courier service or three business days following mailing by registered or certified mail.
		

		
			 
		

		
			16.          GOVERNING LAW.
		

		
			 
		

		
			This Agreement shall be governed by and construed in accordance with the laws of the State of Delaware,  without giving effect to the conflict of law principles thereof For the purpose of litigating any dispute that arises under this Agreement, the parties hereby consent to exclusive jurisdiction in Massachusetts and agree that such litigation shall be conducted in the state courts of Massachusetts or the federal courts of the United States for the District of Massachusetts.
		

		
			 
		

		
			17.          BENEFIT OF AGREEMENT.
		

		
			 
		

		
			Subject to the provisions hereof, this Agreement shall be for the benefit of and shall be binding upon the heirs,  executors, administrators,  successors and assigns of the parties hereto .
		

		
			 
		

		
			18.          ENTIRE AGREEMENT.
		

		
			 
		

		
			This  Agreement embodies the entire agreement and understanding between the parties hereto with respect to the subject matter hereof and supersedes all prior oral or written agreements and understandings relating to the subject matter hereof (with the exception of acceleration of vesting provisions contained in any other agreement with the Company) .  No statement,  representation,  warranty, covenant or agreement not expressly set forth in this Agreement shall affect or be used to interpret,  change or restrict the express  terms and provisions of this Agreement.
		

		
			 
		

		
			19.          MODIFICATIONS AND AMENDMENTS.
		

		
			 
		

		
			The terms and provisions of this Agreement may be modified or amended by the Administrator; provided, however ,  the Administrator not take any action that is considered a direct or indirect “repricing" for purposes of the stockholder approval rules of the applicable securities exchange or inter-dealer quotation system on which the Shares are listed ,  including any other action that is treated as a repricing under generally accepted accounting principles .  Any modification or amendment of this Agreement shall not,  without the consent of the Participant,  adversely affect the Participant's rights under this Agreement,  unless such amendment is required by applicable law .
		

		
			 
		

		
			
		

		
			

		 

		

			10

		

 

		

		
			 
		

		
			20.          WAIVERS AND CONSENTS.
		

		
			 
		

		
			The terms and provisions of this Agreement may be waived, or consent for the departure therefrom granted, only by written document executed by the party entitled to the benefits of such terms or provisions.  No such waiver or consent shall be deemed to be or shall constitute a waiver or consent with respect to any other terms or provisions of this Agreement,  whether or not similar. Each such waiver or consent shall be effective only in the specific instance and for the purpose for which it was given and shall not constitute a continuing waiver or consent.
		

		
			 
		

		
			21.          DATAPRIVACY.
		

		
			 
		

		
			By entering into this Agreement, the Participant: (i) authorizes the Company and each Affiliate ,  and any agent of the Company or any Affiliate facilitating the grant of options under this Agreement, to disclose to the Company or any of its Affiliates such information and data as the Company or any such Affiliate shall request in order to facilitate the grant of options; and (ii) authorizes the Company and each Affiliate to store and transmit such information in electronic form for the purposes set forth in this Agreement.
		

		
			 
		

		
			 
		

		
			 
		

		
			

		 

		

			11

		

 

		

		
			 
		

		
			Exhibit A
		

		
			 
		

		
			NOTICE OF EXERCISE OF STOCK OPTION
		

		
			 
		

		
			[Form for Shares registered in the United States]
		

		
			 
		

		
			To:          Albireo Pharma, Inc.
		

		
			 
		

		
			IMPORTANT NOTICE: This form of Notice of Exercise may only be used at such time as the Company has filed a Registration Statement with the Securities and Exchange Commission under which the issuance of the Shares for which this exercise is being made is registered and such Registration Statement remains effective.
		

		
			 
		

		
			Ladies and Gentlemen:
		

		
			 
		

		
			I hereby exercise  my Stock Option to purchase                                            shares (the "Shares") of the common stock, $0.01 par value, of Albireo Pharma, Inc. (the "Company”),  at the exercise price of $          per share, pursuant to and subject to the terms of that Stock Option Grant Notice dated ------' 201_.
		

		
			 
		

		
			I understand the nature of the investment I am making and the financial risks thereof. I am aware that it is my responsibility to have consulted with competent tax and legal advisors about the relevant national, state and local income tax and securities laws affecting the exercise of the Option and the purchase and subsequent sale of the Shares.
		

		
			 
		

		
			I  am paying the option exercise price for the Shares as follows:
		

		
			 
		

		
			 
		

			
					
						 

					
					
						 

					
					
						 

				
	
					
						 

				
	
					
						Please issue the Shares (check one):

				
	
					
						 

				
	
					
						D to me; or

				
	
					
						 

				
	
					
						D to me and                                                                                           as joint tenants with right of survivorship,

				
	
					
						 

				
	
					
						at the following address:

					
					
						 

				
	
					
						 

					
					
						 

				
	
					
						 

					
					
						 

				
	
					
						 

					
					
						 

				
	
					
						 

					
					
						 

				

		
			 
		

		
			
		

		
			

		 

		

			Exhibit A-1

		

 

		

		
			 
		

		
			My mailing address for stockholder communications, if different from the address listed above, is :
		

		
			 
		

		
			 
		

			
					
						 

					
					
						 

				
	
					
						 

					
					
						 

				
	
					
						 

					
					
						 

				
	
					
						 

					
					
						 

				
	
					
						 

					
					
						 

				
	
					
						 

					
					
						Very truly yours,

				
	
					
						 

					
					
						 

				
	
					
						 

					
					
						 

				
	
					
						 

					
					
						Participant (signature)

				
	
					
						 

					
					
						 

				
	
					
						 

					
					
						 

				
	
					
						 

					
					
						Print Name

				
	
					
						 

					
					
						 

				
	
					
						 

					
					
						 

				
	
					
						 

					
					
						Date

				

		
			 
		

		 

		

			Exhibit A-2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00289-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00289-of-00352.parquet"}]]